Immunophenotype of Hematologic Neoplasms with a Translocation t(8;21)

Haas, OA; Köller, Ursula; Grois, Nicole; Nowotny, H.

doi:10.1007/978-3-642-84895-7_32

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some specific immunophenotypic patterns may suggest recurrent genetic abnormalities. Thus, this may be of great help to direct further specific analysis by fluorescent in situ hybridization or molecular biology (Table ; ).…”

Section: Acute Myeloid Leukemia Panelmentioning

confidence: 99%

First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX

et al. 2014

View full text Add to dashboard Cite

Multiparameter flow cytometry is a highly sensitive, fast, and specific diagnostic technology with a wide range of applicability in hematology. Although well-established eight-color immunophenotyping panels are already available, most Brazilian clinical laboratories are equipped with four-color flow cytometer facilities. Based on this fact, the Brazilian Group of Flow Cytometry (Grupo Brasileiro de Citometria de Fluxo, GBCFLUX) for standardization of clinical flow cytometry has proposed an antibody panel designed to allow precise diagnosis and characterization of acute leukemia (AL) within resource-restricted areas. Morphological analysis of bone marrow smears, together with the screening panel, is mandatory for the primary identification of AL. The disease-oriented panels proposed here are divided into three levels of recommendations (mandatory, recommendable, and optional) in order to provide an accurate final diagnosis, as well as allow some degree of flexibility based on available local resources and patient-GBCFLUX Acute Leukemia Subcommittee: Bacal NS (Hospital

show abstract

Section: Acute Myeloid Leukemia Panelmentioning

confidence: 99%

First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[207][208][209] Also, a distinctive immunophenotypic pattern with expression of myeloid markers as well as CD19 and CD56, but lack of T cell antigens, has been described. 210,211 Clinically, children are older, predominantly male, and have a high incidence of extramedullary tumor masses. 204,209,212,213 They also experience high remission and survival rates, 183,203,204 as compared to other AML-M2 cases 184 or to all AML cases lacking t(8;21).…”

Section: Numerical Abnormalitiesmentioning

confidence: 99%

Molecular cytogenetics of childhood hematological malignancies

Martínez-Climent

1997

Leukemia

View full text Add to dashboard Cite

Cytogenetic and molecular analyses are essential for the classification of childhood hematologic malignancies. Nearly all children with leukemia should have an adequate cytogenetic analysis which in 80-90% is expected to show clonal chromosomal abnormalities. Moreover, with the availability of appropriate gene probes and sophisticated molecular techniques, genetic rearrangements become detectable in the majority of leukemia patients. Genetic abnormalities often associate with particular clinical-biological characteristics of the disease. In ALL, for example, genetic alterations together with distinct immunologic and clinical features, define various subgroups. In AML, unique cytogenetic rearrangements have been identified and associated with distinct morphological subgroups. Apart from the diagnostic assessment, cytogenetic studies provide valuable prognostic information which may influence treatment choices. Molecular analysis has also become of important value in the management of children with leukemias, as it serves, for example, to identify genetic abnormalities not detected by chromosomal analysis and to monitor residual disease during treatment and follow-up. Thus, genetic analyses of leukemic cells provide information of clinical relevance as well as contributing to our understanding of leukemogenesis. Alternative classifications of acute leukemias which take into account genetic information are being proposed. The available cytogenetic and molecular data have then to be included in clinical protocols, either by selecting individualized therapies in certain leukemia subtypes or by modifying treatment according to quantification of residual disease. We are closer to our main goal which is not only to classify 100% of childhood leukemias accurately, but to cure all of them.

show abstract